Bayer's Q2 Numbers Give Bulls Fresh Ammunition, But Missouri Hearing Looms as the Real Catalyst
Published on 08/05/2026 at 18:11 | Redaktion boerse-global.de
The market's reaction to Bayer's latest earnings was swift and unambiguous — but the real test for the German conglomerate's recovery narrative arrives next month, when a Missouri courtroom takes center stage in the company's long-running glyphosate saga.
Shares in the Leverkusen-based group climbed 2.02 percent to €49.38 on Wednesday, building on the previous session's 2.07 percent advance that had closed the stock at €48.40. The two-day rally has brought the equity back within striking distance of the psychologically significant €50 threshold — a level that has repeatedly frustrated investors in recent months. The stock now sits roughly 8 percent below its 52-week high of €53.86, a peak reached in early July shortly after the US Supreme Court handed Bayer a pivotal legal victory.
A Return to Profitability
The catalyst for the renewed optimism was a set of half-year figures that beat consensus expectations across several key metrics. Net income swung to €219 million in the second quarter, a stark reversal from the €199 million loss recorded in the same period a year earlier. Group revenue for the first six months rose 3 percent on a currency- and portfolio-adjusted basis to €24.3 billion, while core earnings per share climbed by the same percentage to €3.66. Adjusted EBITDA expanded 7 percent to €6.6 billion for the half, with the second quarter alone contributing €2.14 billion — up 1.9 percent year-on-year and roughly 11 percent ahead of analyst forecasts.
The quarterly top line came in at €10.9 billion, a 2 percent improvement, though the headline figure masked a pronounced divergence between divisions.
Should investors sell immediately? Or is it worth buying Bayer?
Crop Science Carries the Load
The agricultural unit once again proved to be the engine room of the group. Crop Science posted a 5.5 percent increase in first-half sales, while operating profit jumped 30 percent to €902 million. The division's EBITDA margin reached 31.4 percent for the period, helped by firmer glyphosate pricing and the regulatory approval of dicamba.
Pharmaceuticals painted a more nuanced picture. Second-quarter revenue edged up 1 percent to €4.5 billion, but the growth was entirely driven by the newer portfolio. Nubeqa and Kerendia continued their strong momentum, offsetting steep declines in the mature franchise: Xarelto saw sales fall 42 percent and Eylea dropped 33 percent, both casualties of patent expiries and biosimilar competition. Consumer Health delivered only modest growth over the half.
Debt Dynamics Shift
The balance sheet tells a story of deliberate, if costly, restructuring. Free cash flow deteriorated to minus €2.7 billion for the half, dragged down by litigation-related payments — a widening from the minus €1.4 billion recorded in the prior-year period. Net financial debt stood at €33.6 billion at mid-year.
Yet management used the results to lower its year-end debt target band from €32–33 billion to €29–30 billion, a move enabled in part by a €3 billion capital injection from private equity firm Apollo. The company also placed a $5 billion bond, adding further flexibility. Chief executive Bill Anderson used the earnings call to push back against persistent speculation about a potential breakup of the group, insisting he remains focused on executing a transformation built around five defined priorities.
The Legal Calendar Takes Center Stage
The Supreme Court's late-June ruling — which determined that claims alleging Bayer failed to warn of cancer risks on Roundup labels are not admissible — has fundamentally altered the risk calculus for investors. The decision removed a significant overhang that had weighed on the stock for years.
The next milestone arrives on August 19, when a Missouri court hears arguments on a proposed class-action settlement. The agreement, structured over 21 years, could carry costs of up to $7.25 billion — a figure that, while substantial, offers the kind of certainty that a string of unpredictable jury verdicts never could.
Bayer at a turning point? This analysis reveals what investors need to know now.
Analyst Community Rallies
The earnings release triggered a wave of target-price revisions across the sell-side. UBS's Matthew Weston lifted his target from €52 to €62 with a "Buy" rating, noting that the second-quarter core operating result beat consensus by 10 percent and that the post-results conference call contained no new glyphosate information — a non-issue given the improved legal backdrop. Goldman Sachs's James Quigley raised his target to €63.50, the highest on the Street, maintaining "Buy" and pointing to the pharma pipeline, further glyphosate resolution, and the eventual elimination of the conglomerate discount as the path higher. JPMorgan upgraded the stock to "Overweight" with a €61 target, arguing glyphosate risks are now manageable. The DZ Bank lifted its fair value from €54 to €60, while Deutsche Bank Research reiterated "Buy" at €60, citing the EBITDA beat. Jefferies remains the notable holdout, sticking with "Hold" and a €46 target.
A Broader Market Tailwind
The rally unfolded against a constructive tape in Frankfurt. The DAX advanced 0.8 percent on Tuesday to a record close of 26,202 points, with Bayer among the session's standout performers. The stock has now gained roughly 31 percent since the start of the year, a remarkable recovery that underscores how far sentiment has shifted from the dark days of the litigation overhang.
Whether the €50 level finally gives way on a sustained basis will likely hinge on the Missouri hearing. For now, the combination of operational strength in agriculture, a shrinking debt burden, and a legal calendar that is finally moving toward resolution has given investors something they have not had in years: a reason to be constructive.
Ad
Bayer Stock: New Analysis - 5 August
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
